Are current available therapies disease-modifying in spondyloarthritis?

Best Practice and Research: Clinical Rheumatology

Volumn 24, Issue 5, 2010, Pages 625-635

  Lories, Rik J U ^a   De Vlam, Kurt ^a   Luyten, Frank P ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

ankylosing spondylitis; disease modification; psoriatic arthritis; spondyloarthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CELECOXIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; ANKYLOSIS; CLINICAL FEATURE; CLINICAL STUDY; DISEASE COURSE; EVALUATION; HUMAN; INFLAMMATION; JOINT DESTRUCTION; NONHUMAN; OSSIFICATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ARTHRITIS, PSORIATIC; DISEASE PROGRESSION; HUMANS; SPONDYLITIS, ANKYLOSING;

EID: 78049439518     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2010.05.005     Document Type: Review

References (88)

1. D. Aletaha, and J.S. Smolen The definition and measurement of disease modification in inflammatory rheumatic diseases Rheumatic Diseases Clinics of North America 32 2006 9 44 vii
2. N. Akkoc, L.S. van der, and M.A. Khan Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy Best Practice & Research. Clinical Rheumatology 20 2006 539 557
3. F.P. Luyten, R.J. Lories, and P. Verschueren Contemporary concepts of inflammation, damage and repair in rheumatic diseases Best Practice & Research. Clinical Rheumatology 20 2006 829 848
4. G.A. Wells Patient-driven outcomes in rheumatoid arthritis The Journal of Rheumatology. Supplement 82 2009 33 38
5. T. Pincus, G. Ferraccioli, and T. Sokka Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review Rheumatology (Oxford) 41 2002 1346 1356
6. J.T. Sharp, V. Strand, and H. Leung Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group Arthritis and Rheumatism 43 2000 495 505
7. D. van der Heijde, L. Klareskog, and V. Rodriguez-Valverde Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial Arthritis and Rheumatism 54 2006 1063 1074
8. P.E. Lipsky, D.M. van der Heijde, and E.W. St Clair Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group The New England Journal of Medicine 343 2000 1594 1602
9. E.C. Keystone, A.F. Kavanaugh, and J.T. Sharp Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial Arthritis and Rheumatism 50 2004 1400 1411
10. H.K. Genant, C.G. Peterfy, and R. Westhovens Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial Annals of the Rheumatic Diseases 67 2008 1084 1089
11. N. Nishimoto, J. Hashimoto, and N. Miyasaka Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab Annals of the Rheumatic Diseases 66 2007 1162 1167
12. Y. Yazici, T. Sokka, and T. Pincus Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations Rheumatic Diseases Clinics of North America 35 2009 723 729 vi
13. P. Nash, P.J. Mease, J. Braun, and H.D. van der Seronegative spondyloarthropathies: to lump or split? Annals of the Rheumatic Diseases 64 Suppl. 2 2005 ii9 13
14. E. Kruithof, D. Baeten, and L. De Rycke Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis Arthritis Research & Therapy 7 2005 R569 R580
15. I. van Echteld, A. Cieza, and A. Boonen Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health The Journal of Rheumatology 33 2006 2475 2483
16. D.D. Gladman Natural history of psoriatic arthritis Baillire's Clinical Rheumatology 8 1994 379 394
17. K.B. Sokoll, and P.S. Helliwell Comparison of disability and quality of life in rheumatoid and psoriatic arthritis The Journal of Rheumatology 28 2001 1842 1846
18. R.J. Lories, and D.L.P. Baeten Differences in pathophysiology between rheumatoid arthritis and ankylosing spondylitis Clinical and Experimental Rheumatology 27 2009 S10 S14
19. M. Benjamin, and D. McGonagle The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites Journal of Anatomy 199 2001 503 526
20. R.J. Lories, F.P. Luyten, and K. De Vlam Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis Arthritis Research & Therapy 11 2009 221
21. D. Baeten, H.J. Moller, and J. Delanghe Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis Arthritis and Rheumatism 50 2004 1611 1623
22. B. Vandooren, T. Noordenbos, and C. Ambarus Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis Arthritis and Rheumatism 60 2009 966 975
23. J. Sieper, M. Rudwaleit, and X. Baraliakos The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis Annals of the Rheumatic Diseases 68 Suppl. 2 2009 ii1 44
24. D. McGonagle, R.J. Lories, A. Tan, and M. Benjamin The concept of a synovio-entheseal complex and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond Arthritis and Rheumatism 56 2007 2482 2491
25. L. Marinova-Mutafchieva, R.O. Williams, and K. Funa Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis Arthritis and Rheumatism 46 2002 507 513
26. M.A. Brown Progress in spondylarthritis. Progress in studies of the genetics of ankylosing spondylitis Arthritis Research & Therapy 11 2009 254
27. M. Rihl, A. Klos, L. Kohler, and J.G. Kuipers Infection and musculoskeletal conditions: reactive arthritis Best Practice & Research. Clinical Rheumatology 20 2006 1119 1137
28. P. Jacques, and D. Elewaut Joint expedition: linking gut inflammation to arthritis Mucosal Immunology 1 2008 364 371
29. L. De Rycke, B. Vandooren, and E. Kruithof Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy Arthritis and Rheumatism 52 2005 2146 2158
30. D. McGonagle, H. Marzo-Ortega, and P. O'Connor The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy Arthritis and Rheumatism 46 2002 489 493
31. J. Sieper, H. Appel, J. Braun, and M. Rudwaleit Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes Arthritis and Rheumatism 56 2008 649 656
32. K. De Vlam, R.J. Lories, and F.P. Luyten Mechanisms of pathologic new bone formation Current Rheumatology Reports 8 2006 332 337
33. R.J. Lories, and F.P. Luyten Bone morphogenetic proteins in destructive and remodeling arthritis Arthritis Research & Therapy 9 2007 207
34. M.F. Pittenger, A.M. Mackay, and S.C. Beck Multilineage potential of adult human mesenchymal stem cells Science 284 1999 143 147
35. C. De Bari, F. Dell'Accio, P. Tylzanowski, and F.P. Luyten Multipotent mesenchymal stem cells from adult human synovial membrane Arthritis and Rheumatism 44 2001 1928 1942
36. C. De Bari, F. Dell'Accio, and F.P. Luyten Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age Arthritis and Rheumatism 44 2001 85 95
37. E.A. Jones, A. English, and K. Henshaw Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis Arthritis and Rheumatism 50 2004 817 827
38. F. Dell'Accio, C. De Bari, and F.P. Luyten Microenvironment and phenotypic stability specify tissue formation by human articular cartilage-derived cells in vivo Experimental Cell Research 287 2003 16 27
39. R.J.U. Lories, I. Derese, and F.P. Luyten Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis The Journal of Clinical Investigation 115 2005 1571 1579
40. R.J. Lories, M. Daans, and P. Matthys Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis Arthritis and Rheumatism 54 2006 1736 1746
41. D. Diarra, M. Stolina, and K. Polzer Dickkopf-1 is a master regulator of joint remodeling Nature Medicine 13 2007 156 163
42. S. Uderhardt, D. Diarra, and J. Katzenbeisser Blockade of Dickkopf-1 induces fusion of sacroiliac joints Annals of the Rheumatic Diseases 2009
43. H. Appel, G. Ruiz-Heiland, and J. Listing Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis Arthritis and Rheumatism 60 2009 3257 3262
44. R.J. Lories, and F.P. Luyten Bone morphogenetic protein signaling and arthritis Cytokine & Growth Factor Reviews 20 2009 467 473
45. R.J. Lories, P. Matthys, and I. Derese Ankylosing enthesitis, dactylitis and onychoperiostitis in a mouse model of psoriatic arthritis Annals of the Rheumatic Diseases 63 2004 595 598
46. M.C. Park, S.J. Chung, Y.B. Park, and S.K. Lee Suppression of bone morphogenetic proteins attenuates syndesmophytosis by down-regulating smad pathway in aggrecan-induced spondylitis mice Arthritis and Rheumatism 58 2008 S346
47. M.C. Park, Y.B. Park, and S.K. Lee Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis Scandinavian Journal of Rheumatology 37 2008 200 204
48. D. Daoussis, S.N. Liossis, and E.E. Solomou Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis Arthritis and Rheumatism 62 2009 150 158
49. G. Schett Osteoimmunology in rheumatic diseases Arthritis Research & Therapy 11 2009 210
50. C.T. Ritchlin, S.A. Haas-Smith, and P. Li Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis The Journal of Clinical Investigation 111 2003 821 831
51. B. Vandooren, T. Cantaert, and T. Noordenbos The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation Arthritis and Rheumatism 58 2008 718 729
52. B. Vandooren, L. Melis, and E.M. Veys In vitro spontaneous osteoclastogenesis of human peripheral blood mononuclear cells is not crucially dependent on T lymphocytes Arthritis and Rheumatism 60 2009 1020 1025
53. H. Appel, M. Kuhne, and S. Spiekermann Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis Arthritis and Rheumatism 54 2006 2845 2851
54. H. Appel, M. Kuhne, and S. Spiekermann Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow Arthritis and Rheumatism 54 2006 1805 1813
55. J. Zwerina, S. Hayer, and M. Tohidast-Akrad Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction Arthritis and Rheumatism 50 2004 277 290
56. S.B. Cohen, R.K. Dore, and N.E. Lane Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial Arthritis and Rheumatism 58 2008 1299 1309
57. R. Lafyatis, E.F. Remmers, and A.B. Roberts Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids The Journal of Clinical Investigation 83 1989 1267 1276
58. E. Karouzakis, R.E. Gay, S. Gay, and M. Neidhart Epigenetic control in rheumatoid arthritis synovial fibroblasts Nature Reviews. Rheumatology 5 2009 266 272
59. G.S. Firestein, F. Echeverri, and M. Yeo Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium Proceedings of the National Academy of Sciences of the United States of America 94 1997 10895 10900
60. B. Vandooren, E. Kruithof, and D.T. Yu Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy Arthritis and Rheumatism 50 2004 2942 2953
61. B. Vandooren, N. Yeremenko, and T. Noordenbos Mediators of structural remodeling in peripheral spondylarthritis Arthritis and Rheumatism 60 2009 3534 3545
62. B. Vandooren, T. Cantaert, and M.J. van Lierop Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis Annals of the Rheumatic Diseases 68 2009 1044 1050
63. R.J. Lories, I. Derese, C. De Bari, and F.P. Luyten Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondyloarthritis Arthritis and Rheumatism 56 2007 489 497
64. R.J.U. Lories, I. Derese, J.L. Ceuppens, and F.P. Luyten Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis Arthritis and Rheumatism 48 2003 2807 2818
65. P.J. Mease Psoriatic arthritis assessment and treatment update Current Opinion in Rheumatology 21 2009 348 355
66. W.P. Maksymowych Progress in spondylarthritis. Spondyloarthritis: lessons from imaging Arthritis Research & Therapy 11 2009 222
67. D. van der Heijde, J. Sharp, S. Wassenberg, and D.D. Gladman Psoriatic arthritis imaging: a review of scoring methods Annals of the Rheumatic Diseases 64 Suppl. 2 2005 ii61 ii64
68. W.P. Maksymowych MRI in ankylosing spondylitis Current Opinion in Rheumatology 21 2009 313 317
69. S. Wassenberg, V. Fischer-Kahle, G. Herborn, and R. Rau A method to score radiographic change in psoriatic arthritis Zeitschrift für Rheumatologie 60 2001 156 166
70. A.J. Wanders, R.B. Landewe, and A. Spoorenberg What is the most appropriate radiologic scoring method for ankylosing spondylitis? a comparison of the available methods based on the outcome measures in rheumatology clinical trials filter Arthritis and Rheumatism 50 2004 2622 2632
71. R.F. Willkens, H.J. Williams, and J.R. Ward Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis Arthritis and Rheumatism 27 1984 376 381
72. M. Abu-Shakra, D.D. Gladman, and J.C. Thorne Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome The Journal of Rheumatology 22 1995 241 245
73. P.J. Mease, A.J. Kivitz, and F.X. Burch Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression Arthritis and Rheumatism 50 2004 2264 2272
74. C. Antoni, G.G. Krueger, and K. De Vlam Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Annals of the Rheumatic Diseases 64 2005 1150 1157
75. P.J. Mease, D.D. Gladman, and C.T. Ritchlin Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial Arthritis and Rheumatism 52 2005 3279 3289
76. D. van der Heijde, A. Kavanaugh, and D.D. Gladman Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2 Arthritis and Rheumatism 56 2007 2698 2707
77. A. Wanders, D. van der Heijde, and R. Landewe Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial Arthritis and Rheumatism 52 2005 1756 1765
78. K. Vuolteenaho, T. Moilanen, and E. Moilanen Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process Basic & Clinical Pharmacology & Toxicology 102 2008 10 14
79. D. van der Heijde, R. Landewe, and S. Einstein Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept Arthritis and Rheumatism 58 2008 1324 1331
80. D. van der Heijde, R. Landewe, and X. Baraliakos Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis Arthritis and Rheumatism 58 2008 3063 3070
81. D. van der Heijde, D. Salonen, and B.N. Weissman Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years Arthritis Research & Therapy 11 2009 R127
82. G. Schett, M. Stolina, and D. Dwyer Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis Arthritis and Rheumatism 60 2009 2644 2654
83. X. Baraliakos, J. Listing, and M. Rudwaleit The relationship between inflammation and new bone formation in patients with ankylosing spondylitis Arthritis Research & Therapy 10 2008 R104
84. W.P. Maksymowych, P. Chiowchanwisawakit, and T. Clare Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation Arthritis and Rheumatism 60 2009 93 102
85. D. van der Heijde, R. Landewe, and X. Baraliakos Mri-inflammation of the vertebral unit (vu) only marginally contributes to new syndesmophyte formation in that unit: A multi-level analysis Arthritis and Rheumatism 58 2008 S905
86. X. Baraliakos, J. Listing, R.A. von der, and J. Braun The natural course of radiographic progression in ankylosing spondylitis-evidence for major individual variations in a large proportion of patients The Journal of Rheumatology 36 2009 997 1002
87. R.J. Lories, I. Derese, and F.P. Luyten Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis Rheumatology 47 2008 605 608
88. W.P. Maksymowych, R. Landewe, and B. Conner-Spady Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis Arthritis and Rheumatism 56 2007 1846 1853